Synthetic Biologics, Inc. is a clinical-stage biotechnology company focused on developing targeted, orally delivered therapeutics designed to protect and restore the human microbiome. Founded in 2008 and headquartered in Rockville, Maryland, the company leverages proprietary enzyme-based and small molecule platforms to prevent or treat diseases driven by microbial and inflammatory processes. Its research and development efforts center on reducing the unintended consequences of antibiotic therapy and addressing functional gastrointestinal disorders.
The company’s lead investigational product, ribaxamase (SYN-004), is an oral beta-lactamase enzyme intended to degrade specific intravenous beta-lactam antibiotics in the gastrointestinal tract, thereby preserving beneficial gut flora and potentially reducing the incidence of Clostridioides difficile infection and other antibiotic-associated complications. Additional pipeline candidates include SYN-010, a modified-release formulation aimed at treating irritable bowel syndrome with constipation (IBS-C) by targeting gut microbial metabolites, and further preclinical programs focused on enzyme therapeutics for inflammatory and infectious conditions.
Over the past decade, Synthetic Biologics has advanced multiple candidates through Phase I and Phase II clinical trials, collaborating with academic centers and contract research organizations across North America and Europe. The company maintains strategic partnerships to support manufacturing, regulatory filings and global clinical development. Its operations span the United States, with plans to expand into European markets pending regulatory approval and commercial agreements.
Synthetic Biologics is led by a management team with extensive experience in drug discovery, clinical development and regulatory affairs, supported by a board of directors composed of seasoned executives from the biotechnology and pharmaceutical industries. The company is listed on the NYSE American exchange under the ticker symbol SYN and continues to pursue innovative approaches to microbiome protection and restoration.
AI Generated. May Contain Errors.
Free SYN Stock Alerts